Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis

Tumor Biology

Volumn 36, Issue 11, 2015, Pages 8671-8678

  Li, Hong Xing ^a   Zhao, Wei ^a   Shi, Yan ^a   Li, Ya Na ^a   Zhang, Lian Shuang ^a   Zhang, Hong Qin ^a   Wang, Dong ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antiproliferative; Dimerization; Lung cancer; Metastasis; Methotrexate; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; CYCLIN B1; CYTOCHROME C; JANUS KINASE 2; METHOTREXATE; PROTEIN BCL XL; RETINOIC ACID AMIDE; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; AMIDE; RETINOIC ACID; STAT PROTEIN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; M PHASE CELL CYCLE CHECKPOINT; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

AMIDES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; MICE; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; STAT TRANSCRIPTION FACTORS; TRETINOIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949095730     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3534-8     Document Type: Article

References (38)

1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366:1385–96.
2. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor h induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A. 1995;92:5545–9.
3. Alpan RS, Pardee AB. p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ. 1996;7:893–901.
4. Zeng YX, El-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene. 1996;12:1557–64.
5. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 1994;9:3389–96.
6. Ferraldeschi R, Baka S, Jyoti B, et al. Modern management of small-cell lung cancer. Drugs. 2007;67:2135–52.
7. Simon GR, Turrisi A, American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:324S–39S.
8. Planchard D, Le Péchoux C. Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer. 2011;47:S272–83.
9. Darnell Jr JE. STATs and gene regulation. Science. 1997;277:1630–5.
10. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol. 2006;6:602–12.
11. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295–303.
12. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000–8.
13. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets. 2007;7:91–107.
14. Zhang XF, Wang JF, Matczak E, Proper JA, Groopman JE. Janus kinase 2 is involved in stromal cell-derived factor-1 alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood. 2001;97:3342–8.
15. Soriano SF, Hernanz-Falcon P, Rodriguez-Frade JM, De Ana AM, Garzon R, Carvalho-Pinto C, et al. Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation. J Exp Med. 2002;196:311–21.
16. Orfanos CE, Ehlert R, Gollnick H. The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs. 1987;34:459–503.
17. Kligman AM. The growing importance of topical retinoids in clinical dermatology: a retrospective and prospective analysis. J Am Acad Dermatol. 1998;39:S2–7.
18. Chandraratna RA. Current research and future developments in retinoids: oral and topical agents. Cutis. 1998;61:40–5.
19. Zheng Y, Kramer PM, Lubet RA, Steele VE, Kelloff GJ, Pereira MA. Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. Carcinogenesis. 1999;20:255–60.
20. Liang JY, Fontana JA, Rao JN, Ordonez JV, Dawson MI, Shroot B, et al. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate. 1999;38:228–36.
21. Weber E, Ravi RK, Knudsen ES, Williams JR, Dillehay LE, Nelkin BD, et al. Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression. Int J Cancer. 1999;80:935–43.
22. Mologni L, Ponzanelli I, Bresciani F, Sardiello G, Bergamaschi D, Gianni M, et al. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphtalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood. 1999;93:1045–61.
23. Irving H, Lovat PE, Hewson QC, Malcolm AJ, Pearson AD, Redfern CP. Retinoid induced differentiation of neuroblastoma: comparison between LG69, an RXR-selective analogue and 9-cis retinoic acid. Eur J Cancer. 1998;34:111–7.
24. Dirks PB, Patel K, Hubbard SL, Ackerley C, Hamel PA, Rutka JT. Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. Oncogene. 1997;15:2037–48.
25. Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res. 1996;2:1931–5.
26. Defer GL, Adle-Biassette H, Ricolfi F, Martin L, Authier FJ, Chomienne C, et al. All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neurooncol. 1997;34:169–77.
27. Kaba SE, Kyritsis AP, Conrad C, Gleason MJ, Newman R, Levin VA, et al. The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol. 1997;34:145–51.
28. Bouterfa H, Picht T, Keb D, Herbold C, Noll E, Black PM, et al. Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery. 2000;46:419–30.
29. Rotan R. Retinoids as modulators of tumor cell invasion and metastasis. Semin Cancer Biol. 1991;2:197–208.
30. Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18:545–51.
31. Toyonaga T, Nakano K, Nagano M, et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett. 2003;201:107–16.
32. Sahu RP, Srivastava SK. The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. J Natl Cancer Inst. 2009;101:176–93.
33. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocrinol Relat Cancer. 2008;15:367–90.
34. Lewis RS, Ward AC. Stat5 as a diagnostic marker for leukemia. Expert Rev Mol Diagn. 2008;8:73–82.
35. Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor h- and Sp1-responsive element: involvement of the small GTPaseRhoA. Mol Cell Biol. 1998;18:6962–70.
36. Yamaguchi Y, Watanabe H, Yrdiran S, et al. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res. 1999;5:1147–53.
37. Bai J, Sui J, Demirjian A, Vollmer Jr CM, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005;65:2344–52.
38. Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002;9:1–11.